Brief: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026 10:20
March 12 (Reuters) - Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS Q4 PRETAX PROFIT USD -66 THOUSAND GYRE THERAPEUTICS Q4 REVENUE USD 37.195 MILLION GYRE THERAPEUTICS Q4 OPERATING PROFIT USD 118 THOUSAND Source text: ID:nGNXbkKWrh Further company coverage: [GYRE.O ] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes